Table 2 Univariate analysis of independent determinants of ≥ 50% response at M3, M6, M9 and M12

Gender (F/M; %)

47.0/48.0

53.0/52.0

0.925

39.2/52.4

60.8/47.6

0.266

43.2 ± 42.1

56.8 ± 57.9

0.931

42.9/33.3

57.1/66.7

0.456

Age, years (mean ± SD)

52.5 ± 11.8

49.5 ± 10.9

0.116

53.4 ± 12.0

49.0 ± 10.9

0.039

51.6 ± 12.0

50.2 ± 9.9

0.522

51.9 ± 12.0

50.1 ± 10.3

0.418

MHD at M0 (mean ± SD)

25.0 ± 6.6

20.3 ± 7.2

 < .001

24.0 ± 6.7

20.6 ± 7.2

0.011

21.7 ± 7.1

21.5 ± 7.2

0.900

23.1 ± 6.7

20.7 ± 7.3

0.096

MMD at M0 (mean ± SD)

22.3 ± 7.3

17.2 ± 6.6

 < .001

20.8 ± 7.0

17.3 ± 6.7

0.001

18.8 ± 6.7

17.9 6.9

0.455

19.2 ± 7.0

17.6 ± 6.5

0.223

Migraine form (CM/MEHF; %)

49.2/31.3

50.8/68.8

0.176

44.2/21.4

55.8/78.6

0.104

41.9/50.0

58.1/50.0

0.570

42.2/33.3

57.8/66.7

0.757

Medication overuse (Yes/No; %)

48.0/38.5

52.0/61.5

0.510

43.1/22.2

56.9/77.8

0.302

45.5/12.5

54.5/87.5

0.134

44.2/0.0

55.8/100.0

0.039

HAD A at M0 (mean ± SD)

10.0 ± 4.4

9.0 ± 4.4

0.194

9.9 ± 4.2

8.7 ± 4.5

0.147

9.6 ± 4.4

9.1 ± 4.3

0.541

9.6 ± 4.3

9.2 ± 4.5

0.670

HAD D at M0 (mean ± SD)

8.1 ± 4.9

6.9 ± 4.7

0.121

7.4 ± 5.4

6.9 ± 4.6

0.552

7.2 ± 5.0

6.9 ± 4.7

0.742

7.7 ± 5.1

6.6 ± 4.6

0.233

HIT-6 at M0 (mean ± SD)

69.0 ± 5.9

67.2 ± 5.9

0.075

68.4 ± 6.2

67.6 ± 6.0

0.471

68.5 ± 5.9

67.3 ± 6.2

0.314

68.5 ± 5.7

66.8 ± 6.0

0.144

EQ-5D at M0 (mean ± SD)

0.49 ± 0.31

0.60 ± 0.29

0.025

0.54 ± 0.32

0.59 ± 0.28

0.365

0.55 ± 0.29

0.58 ± 0.31

0.645

0.48 ± 0.31

0.63 ± 0.28

0.012

Psychiatric comorbidities (Yes/No; %)

52.2/42.3

47.8/57.7

0.240

53.6/30.6

46.4/69.4

0.012

58.8/28.6

41.2/71.4

0.002

57.1/26.4

42.9/73.6

0.002

Others comorbidities (Yes/No; %)

52.6/45.1

47.4/54.9

0.427

44.8/40.4

55.2/59.6

0.678

42.9/43.0

57.1/57.0

0.987

40.7/41.3

59.3/58.7

0.957

Triptan responsiveness (Yes/No; %)

45.3/52.9

54.7/47.1

0.436

40.2/46.2

59.8/53.8

0.587

43.0/42.9

53.0/57.1

0.989

40.7/42.9

59.3/57.1

0.861